がんに対するCAR T細胞およびT細胞療法

Brudnoら（Mon,）がこの問題を研究しました。

www.synapsesocial.com/papers/69de37b01c2d3320f8b0be91 — DOI: https://doi.org/10.1001/jama.2024.19462

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. The harmonization of World Health Organization International Nonproprietary Names definitions for cell and cell-based gene therapy substances: when a name is not enough· 2021 · 7 citations
2. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy· 2004 · 457 citations
3. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma· 2016 · 3,137 citations
4. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events· 2020 · 267 citations
5. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells· 2018 · 1,363 citations